跳至主要内容
临床试验/DRKS00023243
DRKS00023243已完成未知

Resistance training as prehabilitation exercise in Mamma-CA - PräMaCa

niklinik Köln, Centrum für integrierte Onkologie (CIO)0 个研究点目标入组 66 人开始时间: 2020年12月17日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
Female

入选标准

  • diagnosed breast cancer
  • at least 12 weeks prior to surgical therapy (breast-conserving therapy (BET) or radical mastectomy with axillary dissection)
  • neo-adjuvant chemotherapy or neo-adjuvant radio-chemotherapy
  • Written and valid declaration of consent from the patient
  • Age> = 18 years

排除标准

  • Neo-adjuvant radiotherapy alone
  • Second malignancies
  • WHO / ECOG performance status> 1
  • Life expectancy <5 months
  • ductal carcinoma
  • metastases
  • All illness situations that do not allow hypertrophy training, in particular:
  • o Clinically manifest heart failure (NYHA III-IV)
  • o Partial or global respiratory failure
  • o Permanent thrombocytopenia <10,000 / µl, e.g. refractory autoimmune thrombocytopenias.
  • o Congenital or acquired thrombocytopathies or coagulation disorders.
  • o Symptomatic CHD (exercise ECG recommended if necessary)
  • o Severe refractory hypertension
  • o Non-adjustable COPD
  • o severe osteoporosis
  • o acute migraines, epilepsy, dizziness
  • Taking antidepressants (SSRIs) and other drugs that affect quality of life
  • Medical or psychological condition (psychomotor deficits) that does not allow the patient to take part in the study
  • unwillingness to pass on personal illness data within the framework of the protocol

研究者

发起方
niklinik Köln, Centrum für integrierte Onkologie (CIO)

相似试验